CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved.

Why UBS thinks the a2 Milk share price won’t be impacted by CEO exit

As a2 Milk’s CEO steps down, UBS reiterates their buy rating and share price target on the fast-growing infant formula company.

The theory that markets are efficient, that is, that the prices of assets reflect all available pieces of information, is an ever interesting one.

The one caveat to this theory of course is news. News flow – in markets – after all represents new and inherently unpredictable information.

Yesterday’s revelation that A2M’s MD and CEO Jayne Hrdlicka would be stepping down, immediately blindsided many. Investors seemed ‘shocked’ – in so far that the a2 Milk share price was clobbered – dropping as much as 6% as the markets revalued the stock based on this new information.

Were investors immediately worried that a2 Milk – a company well versed in executing on its vison (having grown its revenue from NZ$42m in FY11 to NZ1.3bn in FY19) – could no longer make good on its goal of ‘conquering’ the Chinese IMF market without Hrdlicka at the helm?

Benjamin Graham – arguably the most influential investor in history once said:

‘In the short run, the market is a voting machine but in the long run it is a weighing machine.’

It is telling then that today the a2 Milk share price rebounded sharply, up around 2% to $14.28 per share by 11:40 AEDT. The S&P500/ASX 200 by comparison was down.

A2 Milk share price: UBS still says ‘BUY’

Regardless of what the market is doing, UBS seems to be taking the long-run view, today reiterating their BUY rating and 12-month price target of NZ$17.00 on the IMF player.

That’s not to say questions don’t remain over A2M’s prospects or ability to execute on its strategy, mind you. The investment bank, canvasing three central questions pondered: how much IMF market share can A2M capture, what levels of profitability can a2 Milk eventually attain, and does this C-suite shakeup pose a risk to A2M's growth strategy?

In saying that, UBS was quick to point out that the company reiterating its FY20 guidance looks to have helped steady the ship somewhat. On the earnings front, even without Hrdlicka in the top spot, it would be business as usual, according to A2's management.

Specifically, it was again pointed out (from figures already revealed at a2 Milk’s recent AGM) that the company was expecting:

'Revenue in the range of $780 million to $800 million with growth demonstrating strong performance against strategy. EBITDA margin % in 1H20 is expected to be in the range of 31-32% whilst the FY20 EBITDA margin is expected to be in the range of 29-30%.'

It was further pointed out that:

'All other key financial performance and balance sheet metrics remain strong and within our expectations.'

UBS analysts look to have taken solace in the reiteration of these figures, and still estimate double-digit earnings (EPS) growth between FY20 to FY23.

Other factors, such as having ex-CEO Geoffrey Babbidge at the helm on an interim basis and the Board's emphasis on balancing growth with cost efficiencies, also informed UBS’s reiteration of their BUY rating.

Consequently, UBS noted that it has made no modifications to its DCF model.

Practise trading Australian stocks with an IG demo account now

The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG Bank S.A. accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer.

Act on share opportunities today

Go long or short on thousands of international stocks with CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take your position.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.